# Charles River Laboratories International, Inc. (CRL)

> Source: Nexqual · https://nexqual.com/CRL · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Charles River Laboratories International, Inc. (CRL), nexqual.com/CRL" · informational, not investment advice.

**Price:** USD 339.66 (-1.51% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 339.66 · day 337.78–351.21 · 52w 146.2–351.21 · market cap null · NYQ

## Key facts
- Last four reported quarters (through Jun 27, 2026): revenue $4.00B, net income -$238M (-6.0% margin), free cash flow $371M (SEC filings).
- 2 of 80 tracked superinvestors hold CRL (13F, Q2 2026): 0 new, 2 added, 0 reduced, 0 unchanged.
- Total return with dividends: 1Y +77.9% vs S&P 500 +14.9%; 5Y -19.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 2.98, revenue estimate $961M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B | $4.00B |
| Operating income | $590M | $651M | $617M | $227M | $25.2M | $90.1M |
| Net income | $391M | $486M | $475M | $22.2M | -$144M | -$238M |
| EPS (diluted) | $7.60 | $9.48 | $9.22 | $0.20 | -$2.91 | — |
| Free cash flow | $532M | $295M | $365M | $502M | $518M | $371M |
| Operating margin | 16.7% | 16.4% | 14.9% | 5.6% | 0.6% | 2.3% |
| Net margin | 11.0% | 12.2% | 11.5% | 0.5% | -3.6% | -6.0% |
| Revenue growth | +21.1% | +12.3% | +3.9% | -1.9% | -0.9% | — |
| Cash + short-term investments | $242M | — | — | $195M | $214M | — |
| Total debt | $2.66B | $2.71B | $2.65B | $2.24B | $2.14B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 27, 2026)

P/E at fiscal year-ends: Dec 2024 429.2x, Dec 2023 25.6x.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold CRL. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| John Rogers | Ariel Investments | 3.41% | $342M | Added +4.3% |
| Bill Nygren | Oakmark Funds | 0.68% | $508M | Added +4.1% |

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Morgan Stanley | Target raised | Overweight | $300 → $340 |
| 2026-09-28 | Jefferies | Target raised | Buy | $305 → $340 |
| 2026-09-25 | Deutsche Bank | Target raised | Buy | $300 → $320 |
| 2026-09-25 | TD Cowen | Target raised | Buy | $300 → $325 |
| 2026-09-25 | Evercore ISI Group | Target raised | Outperform | $320 → $330 |
| 2026-09-25 | RBC Capital | Target raised | Outperform | $282 → $322 |
| 2026-09-25 | Barclays | Target raised | Overweight | $300 → $330 |
| 2026-09-25 | Mizuho | Target raised | Neutral | $264 → $295 |
| 2026-09-25 | Baird | Target raised | Outperform | $291 → $334 |
| 2026-09-11 | Evercore ISI Group | Target raised | Outperform | $300 → $320 |
| 2026-08-10 | TD Cowen | Target raised | Buy | $235 → $300 |
| 2026-08-07 | Morgan Stanley | Target raised | Overweight | $260 → $300 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +77.9% | -19.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +78.2% | -4.2% |
| Volatility (annualized) | 45.8% | 45.7% |
| Max drawdown | -33.9% (Jan 2026→May 2026) | -77.8% (Oct 2021→Apr 2025) |

## Peers (Diagnostics & Research)
RVTY (Revvity, Inc.) USD 157.36 +0.48% · MEDP (Medpace Holdings, Inc.) USD 653.96 -1.29% · ICLR (ICON plc) USD 185.43 +0.10% · GH (Guardant Health, Inc.) USD 162.94 -2.23% · QGEN (Qiagen N.V.) USD 50.22 +0.44% · LH (Labcorp Holdings Inc.) USD 329.93 +1.91%

## More
Full page: https://nexqual.com/CRL · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by business segment (quarter ended 2026-06-27)

| Line | Revenue | Share | YoY | Operating income | Op. margin |
|---|---|---|---|---|---|
| DSA | $606.5M | 60.4% | -1.9% | $124.4M | 20.5% |
| RMS | $209.5M | 20.9% | -1.8% | $36.3M | 17.3% |
| Manufacturing | $188.1M | 18.7% | -6.3% | $65.6M | 34.9% |
| Corporate costs (not allocated) | — | — | — | -$106.4M | — |
| Total revenue | $1.00B | 100% | — | $119.9M | 11.9% |

## Revenue by product line (quarter ended 2026-06-27)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Cost of services provided (excluding amortization of intangible assets) | $808.3M | 80.5% | -3.9% |
| Cost of products sold (excluding amortization of intangible assets) | $195.8M | 19.5% | +2.3% |
| Total revenue | $1.00B | 100% | — |

## Revenue by region (quarter ended 2026-06-27)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| U.S. | $539.9M | 53.8% | -1.8% |
| Europe | $263.1M | 26.2% | -6.7% |
| Canada | $127.5M | 12.7% | -6.0% |
| Asia Pacific | $60.5M | 6.0% | +11.0% |
| Other | $13.1M | 1.3% | +27.0% |
| Total revenue | $1.00B | 100% | — |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $2.98 | $3.05 | -2.4% | $960.7M | 12 |
| Next quarter (ends 2026-12-31) | $3.33 | $3.24 | +2.6% | $956.5M | 12 |
| Current fiscal year (ends 2026-12-31) | $11.37 | $11.10 | +2.5% | $3.92B | 16 |
| Next fiscal year (ends 2027-12-31) | $12.75 | $12.33 | +3.4% | $4.02B | 16 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-04): ±14.1%; last 8 reports averaged ±7.8%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 62.0% | ±14.1% |
| 2026-12-18 | 56 | 53.5% | ±16.9% |
| 2027-02-19 | 119 | 51.6% | ±23.5% |
| 2027-05-21 | 210 | 50.6% | ±30.4% |